Gastroesophageal reflux disease (GERD) is a common condition that affects millions of people worldwide. It can be stated that a defective esophageal reflux barrier (ERB) is the primary cause that can lead to these disease entities. The goal of this systematic review was to summarize and investigate the current literature regarding the functional and molecular aspects of the ERB in humans and the influence of anti-reflux surgery (ARS) on its improvement.
Materials and Methods:
Pubmed, Embase, MEDLINE, and the Cochrane Library were searched from the earliest available date of each database through April 12, 2026. Outcome measurements of interest were changes in the molecular and cellular components of the ERB, as well as improvement in GERD symptoms measured objectively or subjectively.
Results:
The primary literature search produced 110 results, including six duplicates. After screening on title and abstract, 15 studies were found possibly relevant and underwent full-text critical appraisal, resulting in 14 exclusions. Only the study by Ergun et al. fulfilled the inclusion criteria and was therefore included in this systematic review. This study showed significant improvements after ARS in mucosal integrity, mucosal permeability, and mRNA gene expression of the following molecules: E-cadherin, occludin, claudin 1, claudin 4, zonula occludens-1 and zonula occludens-2.
Conclusion:
ARS is responsible for many anatomical and physiological mechanisms, many of which are not yet fully understood. ARS may have positive effects on the mucosal and functional esophageal reflux barrier; however, further prospective studies need to further elucidate this.
KahrilasPJ, ShaheenNJ, VaeziMF, American Gastroenterological Association. et al.American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology2008;135(4):1383–1391, 91.e1-5.
2.
KatzkaDA, PandolfinoJE, KahrilasPJ. Phenotypes of gastroesophageal reflux disease: Where Rome, Lyon, and Montreal meet. Clin Gastroenterol Hepatol2020;18(4):767–776.
3.
NguyenNT, Abu DayyehB, ChangK, et al.American Foregut Society Cooperative white paper on mechanisms of pathologic reflux and antireflux surgery. Foregut2025;5(1):16–26.
4.
ErgunP, KipcakS, GorguluV, et al.Molecular and functional recovery of esophageal barrier integrity after laparoscopic anti-reflux surgery. Dig Dis Sci2025;70(8):2665–2673.
5.
AltmanDG. Practical statistics for medical research. Chapman and Hal: London; 1991.
6.
WellsGA, SheaB, O’ConellD, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2021.
7.
AranaJ, TovarJA, GarayJ. Abnormal preoperative and postoperative esophageal peristalsis in gastroesophageal reflux. J Pediatr Surg1986;21(8):711–714.
8.
ArnoldBN, DunstCM, GillAB, et al.Postoperative impedance-pH testing is unreliable after Nissen fundoplication with or without giant hiatal hernia repair. J Gastrointest Surg2011;15(9):1506–1512.
9.
ChenH, HuY, FangY, et al.Nrf2 deficiency impairs the barrier function of mouse oesophageal epithelium. Gut2014;63(5):711–719.
10.
EluriS, DellonES. Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: More similarities than differences. Curr Opin Gastroenterol2015;31(4):309–315.
11.
ErikssonSE, JobeBA, AyaziS. Magnetic sphincter augmentation and high-resolution manometry: Impact of biomechanical properties on esophageal motility and clinical significance for selection and outcomes. Dis Esophagus2023;36(Supplement_1):doac092.
12.
ErikssonSE, SariciIS, NguyenJ, et al.The role of mucosal impedance in the assessment of the reflux barrier after Nissen fundoplication. J Gastrointest Surg2025;29(8):102097.
WangD, PatelA, MelloM, et al.Esophagogastric Junction Contractile Integral (EGJ-CI) quantifies changes in EGJ barrier function with surgical intervention. Neurogastroenterol Motil2016;28(5):639–646.
15.
SantacroceG, RossiCM, LentiMV, et al.Understanding tissue injury and remodelling in eosinophilic oesophagitis: Development towards personalised medicine. Gut2025;74(6):996–1007.
16.
GehwolfP, RenzO, BrennerE, et al.Laparoscopic fundoplication and new aspects of neural anatomy at the oesophagogastric junction. BJS Open2020;4(3):400–404.
17.
KaymakT, KayaB, WuggenigP, Swiss EoE Cohort Study Group (SEECS). et al.IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. Gut2023;72(5):821–833.
18.
LiuJ, XiaoY, XuQ, et al.Britannilactone 1-O-acetate induced ubiquitination of NLRP3 inflammasome through TRIM31 as a protective mechanism against reflux esophagitis-induced esophageal injury. Chin Med2024;19(1):118.
19.
SuganumaE, IshikawaT, KitamuraY, et al.Recovery of lower oesophageal barrier function: A pilot study comparing a mixture of atropine and neostigmine and sugammadex: A randomised controlled pilot study. Eur J Anaesthesiol2021;38(8):856‐–864.
20.
MillerL, VegesnaA, KalraA, et al.New observations on the gastroesophageal antireflux barrier. Gastroenterol Clin North Am2007;36(3):601–617, ix.
21.
LiberatiA, AltmanDG, TetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ2009;339:b2700.
22.
ErgunP, KipcakS, Selvi GunelN, et al.Inflammatory responses in esophageal mucosa before and after laparoscopic antireflux surgery. World J Gastrointest Surg2024;16(3):871–881.
23.
ArgüeroJ, SifrimD. Pathophysiology of gastro-oesophageal reflux disease: Implications for diagnosis and management. Nat Rev Gastroenterol Hepatol2024;21(4):282–293.
24.
CampagnoloAM, PristonJ, ThoenRH, et al.Laryngopharyngeal reflux: Diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol2014;18(2):184–191.
25.
RunggaldierD, van SchieB, MartiS, et al.[Current possibilities and challenges in the treatment of laryngopharyngeal reflux]. HNO2023;71(5):294–303.
26.
NortunenM, VäkipartaN, ParkkilaS, et al.Carbonic anhydrases II, IX, and XII in reflux esophagitis. Dig Dis Sci2022;67(5):1761–1772.
27.
JovovB, QueJ, TobeyNA, et al.Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol2011;106(6):1039–1047.
28.
StabenauKA, SamuelsTL, LamTK, et al.Pepsinogen/proton pump co-expression in barrett’s esophageal cells induces cancer-associated changes. Laryngoscope2023;133(1):59–69.
29.
YinCY, ZhangSS, ZhongJT, et al.Pepsin and laryngeal and hypopharyngeal carcinomas. Clin Exp Otorhinolaryngol2021;14(2):159–168.
30.
Al-JanabiJ, HartsuckJA, TangJ. Kinetics and mechanism of pepsinogen activation. J Biol Chem1972;247(14):4628–4632.
31.
KowalikK, KrzeskiA. The role of pepsin in the laryngopharyngeal reflux. Otolaryngol Pol2017;71(6):7–13.
32.
GillGA, JohnstonN, BudaA, et al.Laryngeal epithelial defenses against laryngopharyngeal reflux: Investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin. Ann Otol Rhinol Laryngol2005;114(12):913–921.
33.
BardhanKD, StrugalaV, DettmarPW. Reflux revisited: Advancing the role of pepsin. Int J Otolaryngol2012;2012:646901.
34.
LyrosO, RafieeP, NieL, et al.Wnt/β-catenin signaling activation beyond robust nuclear β-catenin accumulation in nondysplastic barrett’s esophagus: Regulation via dickkopf-1. Neoplasia2015;17(7):598–611.
35.
JungYS, ParkJI. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med2020;52(2):183–191.
36.
ShiX, ChenZ, YangY, et al.Bile reflux gastritis: Insights into pathogenesis, relevant factors, carcinomatous risk, diagnosis, and management. Gastroenterol Res Pract2022;2022:2642551.
37.
YuF, YuC, LiF, et al.Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther2021;6(1):307.
38.
ShulpekovaY, ShirokovaE, ZharkovaM, et al.A recent ten-year perspective: Bile acid metabolism and signaling. Molecules2022;27(6):1983.
39.
ZhangQ, AgostonAT, PhamTH, et al.Acidic bile salts induce epithelial to mesenchymal transition via VEGF signaling in non-neoplastic barrett’s cells. Gastroenterology2019;156(1):130–144 e10.
40.
ZhangML, RanLQ, WuMJ, et al.NF-κB: A novel therapeutic pathway for gastroesophageal reflux disease? World J Clin Cases2022;10(24):8436–8442.
41.
SasakiCT, HajekM, DoukasSG, et al.The role of bile reflux and its related NF-κB activated pathway in progression of hypopharyngeal squamous cell cancer. Oral Oncol2020;105:104668.
42.
KandulskiA, WexT, MönkemüllerK, et al.Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol2010;105(9):1934–1943.
43.
YoshidaN, KatadaK, HandaO, et al.Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med2007;19(2):335–340.
44.
LeeJS, OhTY, AhnBO, et al.Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett’s esophagus: Clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat Res2001;480–481:189–200.
45.
SchietromaM, CarleiF, CeciliaEM, et al.A prospective randomized study of systemic inflammation and immune response after laparoscopic nissen fundoplication performed with standard and low-pressure pneumoperitoneum. Surg Laparosc Endosc Percutan Tech2013;23(2):189–196.
46.
SchietromaM, ColozziS, PessiaB, et al.Laparoscopic Nissen fundoplication: The effects of high-concentration supplemental perioperative oxygen on the inflammatory and immune response: A randomised controlled trial. J Minim Access Surg2018;14(3):221–229.
47.
OhDS, DeMeesterSR, VallbohmerD, et al.Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett’s esophagus with antireflux surgery. Arch Surg2007;142(6):554–559; discussion 9-60.
48.
McHoneyM, EatonS, WadeA, et al.Inflammatory response in children after laparoscopic vs open Nissen fundoplication: Randomized controlled trial. J Pediatr Surg2005;40(6):908–913; discussion 13-4.
